Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study.
abatacept
interstitial lung disease
rheumatoid arthritis
safety
therapy
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
19 Jan 2020
19 Jan 2020
Historique:
received:
31
12
2019
revised:
10
01
2020
accepted:
16
01
2020
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
23
1
2020
Statut:
epublish
Résumé
Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) have been associated with ILD development or progression. The aim of this multicentric retrospective study was to analyze the evolution of ILD in Italian RA-ILD patients treated with abatacept (ABA). All RA-ILD patients treated with ABA for at least six months were retrospectively evaluated. Serology, previous and concurrent therapies, chest high-resolution computer tomography (HRCT), forced vital capacity (FVC), and lung diffusion of carbon monoxide (CO, DLCO) were collected. Forty-four patients were included; HRCT, FVC, and DLCO were analyzed at baseline, at one year, and at the end of follow-up. A remission or a low disease activity of RA was reached in 41/44 patients. Overall, FVC and DLCO remained stable or increased in 86.1% and 91.7% of patients, respectively, while HRCT was stable or improved in 81.4% of them. Previous and concurrent treatments, in particular, methotrexate, serology, age, sex, joint and lung disease duration were not associated with the outcome at univariate analysis. The management of RA-ILD patients remains a critical unmet medical need. Waiting for prospective controlled studies, ABA has shown a good safety profile in our cohort of Italian RA-ILD patients.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) have been associated with ILD development or progression. The aim of this multicentric retrospective study was to analyze the evolution of ILD in Italian RA-ILD patients treated with abatacept (ABA).
METHODS
METHODS
All RA-ILD patients treated with ABA for at least six months were retrospectively evaluated. Serology, previous and concurrent therapies, chest high-resolution computer tomography (HRCT), forced vital capacity (FVC), and lung diffusion of carbon monoxide (CO, DLCO) were collected.
RESULTS
RESULTS
Forty-four patients were included; HRCT, FVC, and DLCO were analyzed at baseline, at one year, and at the end of follow-up. A remission or a low disease activity of RA was reached in 41/44 patients. Overall, FVC and DLCO remained stable or increased in 86.1% and 91.7% of patients, respectively, while HRCT was stable or improved in 81.4% of them. Previous and concurrent treatments, in particular, methotrexate, serology, age, sex, joint and lung disease duration were not associated with the outcome at univariate analysis.
CONCLUSION
CONCLUSIONS
The management of RA-ILD patients remains a critical unmet medical need. Waiting for prospective controlled studies, ABA has shown a good safety profile in our cohort of Italian RA-ILD patients.
Identifiants
pubmed: 31963908
pii: jcm9010277
doi: 10.3390/jcm9010277
pmc: PMC7019755
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Curr Opin Pulm Med. 2019 Sep;25(5):442-449
pubmed: 31365378
Curr Opin Rheumatol. 2016 Jan;28(1):76-82
pubmed: 26599384
BMJ Open. 2019 May 5;9(5):e028466
pubmed: 31061059
BMJ Open. 2014 Aug 14;4(8):e005615
pubmed: 25125479
Thorax. 2014 Mar;69(3):216-22
pubmed: 24127020
Exp Mol Pathol. 2011 Dec;91(3):718-22
pubmed: 21945736
Eur J Rheumatol. 2018 Jul 01;6(3):146-149
pubmed: 31364981
Intern Med. 2019 Jun 15;58(12):1703-1712
pubmed: 30799358
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Rheumatol Ther. 2018 Jun;5(1):283-291
pubmed: 29470834
Mod Rheumatol. 2019 May;29(3):413-417
pubmed: 29798700
N Engl J Med. 2015 Mar 26;372(13):1189-91
pubmed: 25806913
J Rheumatol. 2019 Apr;46(4):360-369
pubmed: 30442831
J Clin Rheumatol. 2014 Dec;20(8):445-6
pubmed: 25417684
Arthritis Res Ther. 2018 Aug 29;20(1):197
pubmed: 30157927
Rev Invest Clin. 2017 Sep-Oct;69(5):235-242
pubmed: 29077694
Arthritis Rheumatol. 2018 Oct;70(10):1544-1554
pubmed: 29806092
Respir Investig. 2016 Sep;54(5):376-9
pubmed: 27566388
Semin Arthritis Rheum. 2018 Aug;48(1):22-27
pubmed: 29422324
Ann Rheum Dis. 2017 Oct;76(10):1700-1706
pubmed: 28611082
Arthritis Res Ther. 2015 Nov 11;17:319
pubmed: 26555431
BMC Pulm Med. 2019 Jun 20;19(1):111
pubmed: 31221137
Front Med (Lausanne). 2019 Oct 23;6:238
pubmed: 31709258
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
RMD Open. 2017 Dec 18;3(2):e000491
pubmed: 29435359
Clin Exp Rheumatol. 2017 May-Jun;35(3):542
pubmed: 28516882
Nat Rev Rheumatol. 2014 May;10(5):284-94
pubmed: 24366321
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Drugs. 2017 Jul;77(11):1221-1233
pubmed: 28608166
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Nihon Rinsho Meneki Gakkai Kaishi. 2012;35(5):433-8
pubmed: 23124086
Semin Arthritis Rheum. 2014 Apr;43(5):613-26
pubmed: 24231065
J Clin Rheumatol. 2017 Mar;23(2):125-126
pubmed: 28225518
Ther Adv Respir Dis. 2017 Jan;11(1):64-72
pubmed: 27733490
Am J Respir Crit Care Med. 2011 Feb 1;183(3):372-8
pubmed: 20851924
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Intern Med J. 2019 Oct 29;:
pubmed: 31661185
Arthritis Rheum. 2010 Jun;62(6):1583-91
pubmed: 20155830